PWRM.OB, NASDAQ:TEVA, MDHI.OB Dr. Stock Pick’s News From Medical Companies.
Tuesday, July 27th, 2010
**************************************************************
Power3 Medical Products, Inc. (OTCBB: PWRM) announced that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro® diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro® diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro® diagnostic tests and the development of new drugs.
“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr. Bosquez.
Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.”
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented recently on the U.S. Food and Drug Administration’s response to a citizen petition questioning the approval criteria for a generic Lovenox® (enoxaparin sodium) injection and its subsequent approval of another generic filer’s Abbreviated New Drug Application (ANDA).
After reviewing the FDA’s response to the citizen petition, which outlines 5 criteria to demonstrate “sameness”, Teva believes that it has demonstrated to the FDA that its version of generic Lovenox meets their criteria and that Teva’s pending ANDA is approvable.
Teva maintains the approval for an ANDA for generic Lovenox is appropriate because:
- The active ingredient in enoxaparin is significantly better characterized than the active ingredients of significantly more complex molecules
- Pharmacologically active portions of enoxaparin can be identified and replicated, and
- In vitro and in vivo PD tests are rapidly indicative of drug efficacy and safety
Teva recognizes and supports FDA authority and discretion to make generic drug approvals on a case-by-case basis considering drug complexity, patient efficacy and safety outcomes.
Given the complexity of Teva’s Copaxone® and the serious, degenerative nature of multiple sclerosis, it is Teva’s belief that any potential generic version of Copaxone should be evaluated via pre-clinical and full-scale, placebo-controlled clinical trials with measured clinical endpoints in multiple sclerosis patients to establish safety, efficacy and immunogenicity in a real patient population.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Western Europe.
Medical Alarm Concepts Holding, Inc. (OTCBB:MDHI), manufacturer of the MediPendant™, the first fully-monitored medical alarm system that allows you to speak and listen directly through the pendant, announces the availability of a new video interview with the Company’s CEO Howard Teicher. The video also includes a demonstration of the superior features, functions and benefits of the revolutionary MediPendant.
“We are extremely excited about the potential of the MediPendant. I encourage everyone to watch the video, which provides a strong understanding of why we believe our personal alarm system is superior to anything on the market today. It is very powerful, user-friendly and gives the customers the freedom and peace of mind to be able to communicate in a two-way manner through the pendant with an EMT-certified operator anytime and anywhere within a 600 feet radius of the home base station. No other system offers this capability. We are very optimistic about our future as we continue to expand our distribution partnerships,” said Howard Teicher, CEO of Medical Alarm Concepts.
Medical Alarm Concepts Holdings, Inc. develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. Medical Alarm Concepts has built their reputation in the personal emergency response system (”PERS”) and medical alert industry. With patented technology and state-of-the-art services, MAC is uniquely positioned to mobilize the right people, skills and alliances to ensure success and client satisfaction. Medical Alarm Concepts design and support philosophy emphasizes industry best practices, while providing polished and savvy solutions. MAC’s latest innovation is the development of its two-way voice speakerphone pendant technology.
**************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
PRGO, Perrigo Co.
TEVA, Teva Pharmaceutical Industries Limited
.png)
.png)
.png)
